Jacqueline Corrigan-Curay, who runs a key FDA center, is the latest top official to depart the agency.
Novo alleges that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”
FDA cuts gutted key conflict of interest staff, raising concerns about transparency, advisory panel delays, and drug oversight under the new commissioner.
Key Republican senators are discussing a provision that would sharply limit federal spending on the Affordable Care Act's Medicaid expansion.
The results that the company’s decision to use a slower dosing schedule to make the drug more tolerable in further testing.
Single dose of psychedelic drug led to a mean reduction of 3.6 points on standard measure of clinical depression with no safety issues raised
While the House One Big Beautiful Bill preserves vital existing Medicaid financing, the Senate bill would have the opposite effect.
“It looks like an alien molecule”: How scientists created Gilead’s new HIV prevention drug lencapavir, or Yeztugo.
